Lucia Anna Muscarella

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3289354/publications.pdf

Version: 2024-02-01

112	6,377	185998	69108
papers	citations	28 h-index	77 g-index

113	113	113	10690
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Comprehensive genomic profiles of small cell lung cancer. Nature, 2015, 524, 47-53.	13.7	1,634
2	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics, 2012, 44, 1104-1110.	9.4	1,186
3	Systemic Human ILC Precursors Provide a Substrate for Tissue ILC Differentiation. Cell, 2017, 168, 1086-1100.e10.	13.5	420
4	A Genomics-Based Classification of Human Lung Tumors. Science Translational Medicine, 2013, 5, 209ra153.	5.8	365
5	A Prognostic DNA Methylation Signature for Stage I Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2013, 31, 4140-4147.	0.8	250
6	CD74â€“NRG1 Fusions in Lung Adenocarcinoma. Cancer Discovery, 2014, 4, 415-422.	7.7	238
7	Integrative and comparative genomic analyses identify clinicallyÂrelevant pulmonary carcinoidÂgroups and unveil the supra-carcinoids. Nature Communications, 2019, 10, 3407.	5.8	132
8	Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer. Epigenetics, 2011, 6, 710-719.	1.3	126
9	Blood Ionized Calcium Is Associated with Clustered Polymorphisms in the Carboxyl-Terminal Tail of the Calcium-Sensing Receptor. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5634-5638.	1.8	115
10	Paraoxonase gene variants are associated with autism in North America, but not in Italy: possible regional specificity in geneâ€“environment interactions. Molecular Psychiatry, 2005, 10, 1006-1016.	4.1	115
11	Diagnosis of Parathyroid Tumors in Familial Isolated Hyperparathyroidism with HRPT2 Mutation: Implications for Cancer Surveillance. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2827-2832.	1.8	100
12	Association between the HOXA1 A218G polymorphism and increased head circumference in patients with autism. Biological Psychiatry, 2004, 55, 413-419.	0.7	94
13	Regulation ofKEAP1expression by promoter methylation in malignant gliomas and association with patientâ€™s outcome. Epigenetics, 2011, 6, 317-325.	1.3	94
14	Primary Hyperparathyroidism and the Presence of Kidney Stones Are Associated with Different Haplotypes of the Calcium-Sensing Receptor. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 277-283.	1.8	83
15	Genomic and evolutionary classification of lung cancer in never smokers. Nature Genetics, 2021, 53, 1348-1359.	9.4	81
16	AberrantKeap1methylation in breast cancer and association with clinicopathological features. Epigenetics, 2013, 8, 105-112.	1.3	77
17	Calcium-Sensing Receptor (CASR) Mutations in Hypercalcemic States: Studies from a Single Endocrine Clinic Over Three Years. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1819-1829.	1.8	70
18	CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort. Cellular Oncology (Dordrecht), 2012, 35, 411-422.	2.1	67

#	Article	IF	Citations
19	Hemangioblastomas of Central Nervous System: Molecular Genetic Analysis and Clinical Management. Neurosurgery, 2005, 56, 1215-1221.	0.6	64
20	Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma. Oncotarget, 2017, 8, 11187-11198.	0.8	64
21	Epigenetic versus Genetic Deregulation of the KEAP1/NRF2 Axis in Solid Tumors: Focus on Methylation and Noncoding RNAs. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-21.	1.9	41
22	High RAD51 mRNA expression characterize estrogen receptorâ€positive/progesteron receptorâ€negative breast cancer and is associated with patient's outcome. International Journal of Cancer, 2011, 129, 536-545.	2.3	40
23	Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591881559.	1.4	38
24	Nrf2 and Notch Signaling in Lung Cancer: Near the Crossroad. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-17.	1.9	36
25	Frequent NRG1 fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression. Oncotarget, 2018, 9, 9661-9671.	0.8	36
26	Diagnostic and Prognostic Value of B4GALT1 Hypermethylation and Its Clinical Significance as a Novel Circulating Cell-Free DNA Biomarker in Colorectal Cancer. Cancers, 2019, 11, 1598.	1.7	35
27	Molecular Analysis of NPHS2 and ACTN4 Genes in a Series of 33 Italian Patients Affected by Adult-Onset Nonfamilial Focal Segmental Glomerulosclerosis. Nephron Clinical Practice, 2005, 99, c31-c36.	2.3	33
28	Clinicopathologic Features and Response to Therapy ofNRG1Fusionâ€“Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. Journal of Clinical Oncology, 2021, 39, 2791-2802.	0.8	32
29	Therapeutic Potential of Afatinib inNRG1Fusion-Driven Solid Tumors: A Case Series. Oncologist, 2021, 26, 7-16.	1.9	31
30	Enhanced APOE2 transmission rates in families with autistic probands. Psychiatric Genetics, 2004, 14, 73-82.	0.6	29
31	Molecular analysis of the HuD gene in neuroendocrine lung cancers. Lung Cancer, 2010, 67, 69-75.	0.9	27
32	HOXA1gene variants influence head growth rates in humans. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 388-390.	1.1	26
33	Extraneuraxial Hemangioblastoma: Clinicopathologic Features and Review of the Literature. Advances in Anatomic Pathology, 2018, 25, 197-215.	2.4	24
34	Gene expression of muscular and neuronal pathways is cooperatively dysregulated in patients with idiopathic achalasia. Scientific Reports, 2016, 6, 31549.	1.6	23
35	NRF2 Regulation by Noncoding RNAs in Cancers: The Present Knowledge and the Way Forward. Cancers, 2020, 12, 3621.	1.7	21
36	Gene expression of somatostatin receptor subtypes SSTR2a, SSTR3 and SSTR5 in peripheral blood of neuroendocrine lung cancer affected patients. Cellular Oncology (Dordrecht), 2011, 34, 435-441.	2.1	20

#	Article	IF	Citations
37	Comparison of circadian characteristics for cytotoxic lymphocyte subsets in non-small cell lung cancer patients versus controls. Clinical and Experimental Medicine, 2012, 12, 181-194.	1.9	19
38	EZH2 and ZFX oncogenes in malignant behaviour of parathyroid neoplasms. Endocrine, 2016, 54, 55-59.	1.1	19
39	NRG1-ErbB Lost in Translation: A New Paradigm for Lung Cancer?. Current Medicinal Chemistry, 2017, 24, 4213-4228.	1.2	19
40	Identification and Functional Characterization of Three NoLS (Nucleolar Localisation Signals) Mutations of the CDC73 Gene. PLoS ONE, 2013, 8, e82292.	1.1	18
41	Coexistence of multiple endocrine neoplasia type 1 and type 2 in a large Italian family. Endocrine, 2011, 40, 481-485.	1.1	17
42	A rare S33C mutation of CTNNB1 encoding Î²-catenin in a parathyroid adenoma found in an Italian primary hyperparathyroid cohort. Endocrine, 2012, 41, 152-155.	1.1	17
43	Extraneuraxial hemangioblastoma: A clinicopathologic study of 10 cases with molecular analysis of the VHL gene. Pathology Research and Practice, 2018, 214, 1156-1165.	1.0	17
44	ALK and NRG1 Fusions Coexist in a Patient with Signet Ring Cell Lung Adenocarcinoma. Journal of Thoracic Oncology, 2017, 12, e161-e163.	0.5	16
45	Methylation Density Pattern of KEAP1 Gene in Lung Cancer Cell Lines Detected by Quantitative Methylation Specific PCR and Pyrosequencing. International Journal of Molecular Sciences, 2019, 20, 2697.	1.8	15
46	Effects of KEAP1 Silencing on the Regulation of NRF2 Activity in Neuroendocrine Lung Tumors. International Journal of Molecular Sciences, 2019, 20, 2531.	1.8	15
47	NRG1: a cinderella fusion in lung cancer?. Lung Cancer Management, 2017, 6, 121-123.	1.5	14
48	Gene expression profile in metastatic and non-metastatic parathyroid carcinoma. Endocrine-Related Cancer, 2021, 28, 111-134.	1.6	14
49	Alteration of Hypothalamicâ€“Pituitaryâ€“Thyroid Axis Function in Non-Small-Cell Lung Cancer Patients. Integrative Cancer Therapies, 2012, 11, 327-336.	0.8	13
50	Targeting emerging molecular alterations in the treatment of non-small cell lung cancer: current challenges and the way forward. Expert Opinion on Investigational Drugs, 2020, 29, 363-372.	1.9	13
51	Identification of two novel mutations and of a novel critical region in the KRIT1 gene. Neurogenetics, 2007, 8, 29-37.	0.7	12
52	Molecular Dissection of the VHL Gene in Solitary Capillary Hemangioblastoma of the Central Nervous System. Journal of Neuropathology and Experimental Neurology, 2014, 73, 50-58.	0.9	12
53	Alterations of DNA methylation in parathyroid tumors. Molecular and Cellular Endocrinology, 2018, 469, 60-69.	1.6	12
54	Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis. Oncotarget, 2021, 12, 1470-1489.	0.8	12

#	Article	IF	Citations
55	Large deletion at the CDC73 gene locus and search for predictive markers of the presence of a CDC73 genetic lesion. Oncotarget, 2018, 9, 20721-20733.	0.8	12
56	Molecular detection of neuron-specific ELAV-like-positive cells in the peripheral blood of patients with small-cell lung cancer. Cellular Oncology, 2008, 30, 291-7.	1.9	12
57	Circadian Aspects of Growth Hormoneâ€“Insulin-Like Growth Factor Axis Function in Patients With Lung Cancer. Clinical Lung Cancer, 2012, 13, 68-74.	1.1	11
58	Human bronchial carcinoid tumor initiating cells are targeted by the combination of acetazolamide and sulforaphane. BMC Cancer, 2019, 19, 864.	1.1	11
59	NRG1 fusion-positive lung cancers: Clinicopathologic profile and treatment outcomes from a global multicenter registry.. Journal of Clinical Oncology, 2019, 37, 9081-9081.	0.8	11
60	Small Deletion at the 7q21.2 Locus in a CCM Family Detected by Real-Time Quantitative PCR. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-7.	3.0	10
61	FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities. BMC Cancer, 2014, 14, 396.	1.1	10
62	Liquid biopsy and NSCLC. Lung Cancer Management, 2016, 5, 91-104.	1.5	10
63	Potential Prognostic Role of SPARC Methylation in Non-Small-Cell Lung Cancer. Cells, 2020, 9, 1523.	1.8	10
64	Hormone and Cytokine Orcadian Alteration in Non-Small Cell Lung Cancer Patients. International Journal of Immunopathology and Pharmacology, 2012, 25, 691-702.	1.0	9
65	VHLFrameshift Mutation as Target of Nonsense-Mediated mRNA Decay inDrosophila melanogasterand Human HEK293 Cell Line. Journal of Biomedicine and Biotechnology, 2009, 2009, 1-9.	3.0	8
66	Candidate gene study of HOXB1 in autism spectrum disorder. Molecular Autism, 2010, 1, 9.	2.6	8
67	Antiphase signalling in the neuroendocrine-immune system in healthy humans. Biomedicine and Pharmacotherapy, 2011, 65, 275-279.	2.5	8
68	Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 1281-1288.	1.5	8
69	Establishment and genetic characterization of ANGM-CSS, a novel, immortal cell line derived from a human glioblastoma multiforme. International Journal of Oncology, 2014, 44, 717-724.	1.4	7
70	Epigenetic Scanning of KEAP1 CpG Sites Uncovers New Molecular-Driven Patterns in Lung Adeno and Squamous Cell Carcinomas. Antioxidants, 2020, 9, 904.	2.2	7
71	Stage dependent destructuration of neuro-endocrine-immune system components in lung cancer patients. Biomedicine and Pharmacotherapy, 2011, 65, 69-76.	2.5	6
72	Aberrant Genes Promoter Methylation in Neural Crest-Derived Tumors. International Journal of Biological Markers, 2012, 27, 389-394.	0.7	6

#	Article	IF	Citations
73	Identification of EML4-ALK fusion in a sporadic case of cholangiocarcinoma. European Journal of Internal Medicine, 2020, 71, 92-94.	1.0	6
74	An 11-bp duplication in the promoter region of the VHL gene in a patient with cerebellar hemangioblastoma and renal oncocytoma. Journal of Human Genetics, 2007, 52, 485-491.	1.1	5
75	Identification of a novel RUNX2 gene mutation in an Italian family with cleidocranial dysplasia. European Journal of Orthodontics, 2011, 33, 498-502.	1.1	5
76	Keap1/Nrf2 impairing revised: are we missing the single nucleotide polymorphisms?. Journal of Thoracic Disease, 2016, 8, E1752-E1754.	0.6	5
77	Automated Workflow for Somatic and Germline Next Generation Sequencing Analysis in Routine Clinical Cancer Diagnostics. Cancers, 2019, 11, 1691.	1.7	5
78	A malignant inflammatory myofibroblastic tumor of the hypopharynx harboring the 3a/b variants of the EML4-ALK fusion gene. Oncology Letters, 2017, 13, 593-598.	0.8	4
79	Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option. Annals of Oncology, 2019, 30, v791-v792.	0.6	4
80	NRG1 and NRG2 fusions in non-small cell lung cancer (NSCLC): seven years between lights and shadows. Expert Opinion on Therapeutic Targets, 2021, 25, 865-875.	1.5	4
81	Novel mutations of dystrophin gene in DMD patients detected by rapid scanning in biplex exons DHPLC analysis. New Biotechnology, 2007, 24, 231-236.	2.7	3
82	Chronobiologic study of neuro-endocrine axis hormone sequence signalling in healthy men. Biomedicine and Aging Pathology, 2011, 1, 129-137.	0.8	3
83	VHL Gene Alterations in Italian Patients with Isolated Renal Cell Carcinomas. International Journal of Biological Markers, 2013, 28, 208-215.	0.7	3
84	Neuroendocrine-Related Circulating Transcripts in Small-Cell Lung Cancers: Detection Methods and Future Perspectives. Cancers, 2021, 13, 1339.	1.7	3
85	Abstract 2397: Epigenetic silencing in clear renal cell carcinoma: KEAP1 promoter hypermethylation. Cancer Research, 2017, 77, 2397-2397.	0.4	3
86	The Post-Surgical Long-Term Behaviour of Lung Carcinoid Tumours. Indian Journal of Surgery, 2015, 77, 481-485.	0.2	2
87	REDOXI-miRNA of Keap1/Nrf2 axis in lung tumors. Annals of Oncology, 2019, 30, ii5.	0.6	2
88	P1.14-25 Targeting NRG1-Fusions in Lung Adenocarcinoma: Afatinib as a Novel Potential Treatment Strategy. Journal of Thoracic Oncology, 2019, 14, S563.	0.5	2
89	Rapid EGFR evaluation from used H&E, IHC and FISH diagnostic slides with the Idylla platform. Journal of Clinical Pathology, 2021, , jclinpath-2020-207315.	1.0	2
90	NRG1-fusion-driven solid tumours: A case series indicating the therapeutic potential of afatinib. Annals of Oncology, 2019, 30, ix23-ix24.	0.6	2

#	Article	IF	Citations
91	Neuroendocrine axes function in healthy aging: Evaluation of predictive and manipulable blood serum indexes. Biomedicine and Aging Pathology, 2011, 1, 16-21.	0.8	1
92	Age-related changes of GH-IGF1 axis function. Biomedicine and Aging Pathology, 2011, 1, 39-45.	0.8	1
93	P2.14-14 Comparison of Molecular Testing Modalities for Detection of NRG1 Rearrangements in Invasive Mucinous Adenocarcinoma. Journal of Thoracic Oncology, 2019, 14, S834-S835.	0.5	1
94	NRGÂfusions in tumors: moving from the past to future knowledge. Future Oncology, 2021, 17, 487-490.	1.1	1
95	Abstract 5358: Multi-omics comparative analyses of pulmonary typical carcinoids, atypical carcinoids, and large-cell neuroendocrine carcinoma. , 2018, , .		1
96	Menin and EZH2 activities modulate the expression of the long non-coding RNA HAR1B in parathyroid tumors. Endocrine Abstracts, 0, , .	0.0	1
97	Mixed Pulmonary Adenocarcinoma and Atypical Carcinoid: A Report of Two Cases of a Non-codified Entity With Biological Profile. Frontiers in Molecular Biosciences, 2021, 8, 784876.	1.6	1
98	602 Frequent Epigenetic Inactivation of KEAP1 Gene in Breast Cancer. European Journal of Cancer, 2012, 48, S143.	1.3	0
99	BRAF mutations in sarcomatoid and large cell carcinoma of the lung. Human Pathology, 2017, 63, 218-220.	1.1	0
100	P2.14-32 Epigenetic Silencing of SPARC in NSCLCs. Journal of Thoracic Oncology, 2019, 14, S841.	0.5	0
101	Abstract 3926: Rad51 expression is associated with estrogen and progesteron receptor status in sporadic breast cancer. , 2010, , .		0
102	Abstract 65: Regulation of KEAP1 expression by promoter methylation in malignant gliomas and association with patient's outcome. , 2011, , .		0
103	Abstract 3148: Frequent epigenetic inactivation of keap1 gene in non small cell lung cancer. , 2012, , .		0
104	Abstract 664: Aberrant KEAP1 promoter methylation is associated with disease progression in breast cancer patients treated with epirubicin/cyclophosfamide and docetaxel chemotherapy.. , 2013, , .		0
105	Hypermethylation of the KEAP1 gene in colorectal cancer and association with disease progression.. Journal of Clinical Oncology, 2013, 31, e14655-e14655.	0.8	0
106	Abstract 2251: nrf2-keap1 axis molecular profile in small cell lung cancer cell lines. , 2014, , .		0
107	Abstract 3841: Effects ofKEAP1genetic and epigenetic silencing in SCLC cell lines. , 2015, , .		0
108	Abstract 3843: Nrf2-keap1 axis: uncovers molecular profile in lung carcinoids. , 2015, , .		0

#	Article	IF	Citations
109	Abstract 494: FrequentNRG1genomic rearrangements in invasive mucinous adenocarcinoma from caucasian patients. , 2017, , .		0
110	Abstract 4441: Unveil the role of cell-free circulating microRNA in lung cancer. , 2017, , .		0
111	Abstract 4887: RecurrentNRG1rearrangements in Caucasian pulmonary mucinous adenocarcinoma: results from an Italian multi-center cohort. , 2019, , .		0
112	NRG1 Fusion-Positive Lung Cancers: Clinicopathologic Profile and Treatment Outcomes from a Global Multicenter Registry. , 2019, , .		0